Your browser doesn't support javascript.
loading
Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants.
Iaconis, Daniela; Bordi, Licia; Matusali, Giulia; Talarico, Carmine; Manelfi, Candida; Cesta, Maria Candida; Zippoli, Mara; Caccuri, Francesca; Bugatti, Antonella; Zani, Alberto; Filippini, Federica; Scorzolini, Laura; Gobbi, Marco; Beeg, Marten; Piotti, Arianna; Montopoli, Monica; Cocetta, Veronica; Bressan, Silvia; Bucci, Enrico M; Caruso, Arnaldo; Nicastri, Emanuele; Allegretti, Marcello; Beccari, Andrea R.
Afiliação
  • Iaconis D; Dompé farmaceutici S.p.A., Naples, Italy.
  • Bordi L; National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Matusali G; National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Talarico C; Dompé farmaceutici S.p.A., Naples, Italy.
  • Manelfi C; Dompé farmaceutici S.p.A., L'Aquila, Italy.
  • Cesta MC; Dompé farmaceutici S.p.A., L'Aquila, Italy. candida.cesta@dompe.com.
  • Zippoli M; Dompé farmaceutici S.p.A., Naples, Italy.
  • Caccuri F; Department of Molecular and Translational Medicine, Section of Microbiology and Virology, University of Brescia Medical School, Brescia, Italy.
  • Bugatti A; Department of Molecular and Translational Medicine, Section of Microbiology and Virology, University of Brescia Medical School, Brescia, Italy.
  • Zani A; Department of Molecular and Translational Medicine, Section of Microbiology and Virology, University of Brescia Medical School, Brescia, Italy.
  • Filippini F; Department of Molecular and Translational Medicine, Section of Microbiology and Virology, University of Brescia Medical School, Brescia, Italy.
  • Scorzolini L; National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Gobbi M; Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Beeg M; Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Piotti A; Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Montopoli M; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, VIMM Veneto Institute Molecular Medicine, Padua, Italy.
  • Cocetta V; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, VIMM Veneto Institute Molecular Medicine, Padua, Italy.
  • Bressan S; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, VIMM Veneto Institute Molecular Medicine, Padua, Italy.
  • Bucci EM; Sbarro Health Research Organization, Biology Department CFT, Temple University, Philadelphia, PA, USA.
  • Caruso A; Department of Molecular and Translational Medicine, Section of Microbiology and Virology, University of Brescia Medical School, Brescia, Italy.
  • Nicastri E; National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Allegretti M; Dompé farmaceutici S.p.A., L'Aquila, Italy.
  • Beccari AR; Dompé farmaceutici S.p.A., Naples, Italy.
Cell Death Dis ; 13(5): 498, 2022 05 25.
Article em En | MEDLINE | ID: mdl-35614039
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article